Cargando…

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and ox...

Descripción completa

Detalles Bibliográficos
Autores principales: Kays, Joshua K., Shahda, Safi, Stanley, Melissa, Bell, Teresa M., O'Neill, Bert H., Kohli, Marc D., Couch, Marion E., Koniaris, Leonidas G., Zimmers, Teresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104116/
https://www.ncbi.nlm.nih.gov/pubmed/29978562
http://dx.doi.org/10.1002/jcsm.12307
_version_ 1783349428865728512
author Kays, Joshua K.
Shahda, Safi
Stanley, Melissa
Bell, Teresa M.
O'Neill, Bert H.
Kohli, Marc D.
Couch, Marion E.
Koniaris, Leonidas G.
Zimmers, Teresa A.
author_facet Kays, Joshua K.
Shahda, Safi
Stanley, Melissa
Bell, Teresa M.
O'Neill, Bert H.
Kohli, Marc D.
Couch, Marion E.
Koniaris, Leonidas G.
Zimmers, Teresa A.
author_sort Kays, Joshua K.
collection PubMed
description BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy. METHODS: We performed a retrospective review of 53 patients with advanced PDAC on 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivariate analysis were performed. RESULTS: Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat Wasting (MFW), while 17% had Fat‐Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall median survival (OMS) of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (P = 0.02). FW (HR = 5.2; 95% confidence interval = 1.5–17.3) and MFW (HR = 1.8; 95% confidence interval = 1.1–2.9) were associated with an increased risk of mortality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. On multivariate analysis, cachexia phenotype and chemotherapy response were independently associated with survival. Notably, CT‐based body composition analysis detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%. CONCLUSIONS: Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage, diagnosis, and first‐line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality. Adipose tissue should be studied for its mechanistic contributions to cachexia.
format Online
Article
Text
id pubmed-6104116
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61041162018-08-27 Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer Kays, Joshua K. Shahda, Safi Stanley, Melissa Bell, Teresa M. O'Neill, Bert H. Kohli, Marc D. Couch, Marion E. Koniaris, Leonidas G. Zimmers, Teresa A. J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy. METHODS: We performed a retrospective review of 53 patients with advanced PDAC on 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivariate analysis were performed. RESULTS: Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat Wasting (MFW), while 17% had Fat‐Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall median survival (OMS) of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (P = 0.02). FW (HR = 5.2; 95% confidence interval = 1.5–17.3) and MFW (HR = 1.8; 95% confidence interval = 1.1–2.9) were associated with an increased risk of mortality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. On multivariate analysis, cachexia phenotype and chemotherapy response were independently associated with survival. Notably, CT‐based body composition analysis detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%. CONCLUSIONS: Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage, diagnosis, and first‐line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality. Adipose tissue should be studied for its mechanistic contributions to cachexia. John Wiley and Sons Inc. 2018-07-05 2018-08 /pmc/articles/PMC6104116/ /pubmed/29978562 http://dx.doi.org/10.1002/jcsm.12307 Text en © 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Kays, Joshua K.
Shahda, Safi
Stanley, Melissa
Bell, Teresa M.
O'Neill, Bert H.
Kohli, Marc D.
Couch, Marion E.
Koniaris, Leonidas G.
Zimmers, Teresa A.
Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title_full Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title_fullStr Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title_full_unstemmed Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title_short Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
title_sort three cachexia phenotypes and the impact of fat‐only loss on survival in folfirinox therapy for pancreatic cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104116/
https://www.ncbi.nlm.nih.gov/pubmed/29978562
http://dx.doi.org/10.1002/jcsm.12307
work_keys_str_mv AT kaysjoshuak threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT shahdasafi threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT stanleymelissa threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT bellteresam threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT oneillberth threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT kohlimarcd threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT couchmarione threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT koniarisleonidasg threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer
AT zimmersteresaa threecachexiaphenotypesandtheimpactoffatonlylossonsurvivalinfolfirinoxtherapyforpancreaticcancer